{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:52:56Z","timestamp":1794527576175,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12018X07"],"award-info":[{"award-number":["SHDC12018X07"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["201940255"],"award-info":[{"award-number":["201940255"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["19411968000"],"award-info":[{"award-number":["19411968000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD, OMIM #301500) is an X-linked lysosomal disorder caused by the deficiency of \u03b1-galactosidase A (\u03b1-GalA), encoded by the <jats:italic>GLA<\/jats:italic> gene. Among more than 1100 reported <jats:italic>GLA<\/jats:italic> mutations, few were deep intronic mutations which have been linked to classic and cardiac variants of FD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>We report a novel hemizygous deep intronic <jats:italic>GLA<\/jats:italic> mutation (IVS4+1326C&gt;T) in a 33-year-old Chinese man with a mild \u03b1-GalA deficiency phenotype involving isolated proteinuria and predominant globotriaosylceramide deposits in podocytes. IVS4+1326C&gt;T, which appears to be the first deep intronic <jats:italic>GLA<\/jats:italic> mutation associated with renal variant of FD, was identified by Sanger sequencing the\u00a0entire\u00a0<jats:italic>GLA<\/jats:italic> genomic DNA sequence of the patient\u2019s peripheral mononuclear blood lymphocytes (PBMCs). Further sequencing of cDNA from PBMCs of the patient revealed a minor full-length <jats:italic>GLA<\/jats:italic> transcript accounting for about 25% of total <jats:italic>GLA<\/jats:italic> transcript, along with two major aberrantly spliced <jats:italic>GLA<\/jats:italic> transcripts encoding mutant forms of \u03b1-GalA with little enzyme activity characterized by in vitro \u03b1-GalA overexpression system in the HEK293T cells. Thus, the combined clinical phenotype, genetic analysis and functional studies verified the pathogenicity of IVS4+1326C&gt;T.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The identification of IVS4+1326C&gt;T establishes a link between deep intronic <jats:italic>GLA<\/jats:italic> mutation and the renal variant of FD, which extends the mutation spectrum in <jats:italic>GLA<\/jats:italic> gene and justifies further study of how IVS4+1326C&gt;T and potentially other deep intronic <jats:italic>GLA<\/jats:italic> mutations contribute to Fabry podocytopathy through aberrant splicing. Future studies should also assess the true incidence of IVS4+1326C&gt;T in patients with different variants of FD, which may improve early genetic diagnosis to allow timely treatment that can prevent disease progression and improve survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02377-8","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:09:04Z","timestamp":1655723344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C&gt;T) causing renal variant of Fabry disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Xuantong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng-Ru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1887-545X","authenticated-orcid":false,"given":"Fujun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"issue":"3","key":"2377_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25(3):769\u201375.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2377_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ndt\/gfaa324","volume":"37","author":"A Nagata","year":"2021","unstructured":"Nagata A, Nasu M, Kaida Y, Nakayama Y, Kurokawa Y, Nakamura N, Shibata R, Hazama T, Tsukimura T, Togawa T, et al. Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrol Dial Transplant. 2021;37(1):115\u201325.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2377_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int. 2003;64(3):801\u20137.","journal-title":"Kidney Int"},{"issue":"8","key":"2377_CR4","doi-asserted-by":"publisher","first-page":"e0161330","DOI":"10.1371\/journal.pone.0161330","volume":"11","author":"X Pan","year":"2016","unstructured":"Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, Xu Y, Ni L, Yu X, Chen X, et al. Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease. PLoS ONE. 2016;11(8):e0161330.","journal-title":"PLoS ONE"},{"issue":"5","key":"2377_CR5","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S0272-6386(04)01094-7","volume":"44","author":"D Rosenthal","year":"2004","unstructured":"Rosenthal D, Lien YH, Lager D, Lai LW, Shang S, Leung N, Fervenza FC. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease. Am J Kidney Dis. 2004;44(5):e85-89.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2377_CR6","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1053\/j.ajkd.2005.01.036","volume":"45","author":"M Cybulla","year":"2005","unstructured":"Cybulla M, Schaefer E, Wendt S, Ling H, Kr\u00f6ber SM, H\u00f6velborn U, Schandelmaier S, Rohrbach R, Neumann HP. Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis. 2005;45(5):e82-89.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2377_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","volume":"21","author":"H Maruyama","year":"2019","unstructured":"Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21(1):44\u201352.","journal-title":"Genet Med"},{"issue":"3","key":"2377_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nephro.2021.03.002","volume":"17","author":"C Vigneau","year":"2021","unstructured":"Vigneau C, Germain DP, Larmet D, Jabbour F, Hourmant M. Screening for Fabry disease in male patients with end-stage renal disease in western France. Nephrol Ther. 2021;17(3):180\u20134.","journal-title":"Nephrol Ther"},{"issue":"1","key":"2377_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfl528","volume":"22","author":"M Merta","year":"2007","unstructured":"Merta M, Reiterova J, Ledvinova J, Poupetov\u00e1 H, Dobrovolny R, Rysav\u00e1 R, Maixnerov\u00e1 D, Bultas J, Mot\u00e1n J, Slivkova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant. 2007;22(1):179\u201386.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2377_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1159\/000494678","volume":"43","author":"CJ Lin","year":"2018","unstructured":"Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, Chen HH, Hwu WL, Wu CJ. Results of Fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a Northern Taiwan Medical Center. Kidney Blood Press Res. 2018;43(5):1636\u201345.","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"2377_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1159\/000452605","volume":"41","author":"K Turkmen","year":"2016","unstructured":"Turkmen K, Guclu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, Seng\u00fcl E, Ozkan O, Emre H, Turgut F, et al. The prevalence of fabry disease in patients with chronic kidney disease in Turkey: the TURKFAB study. Kidney Blood Press Res. 2016;41(6):1016\u201324.","journal-title":"Kidney Blood Press Res"},{"issue":"23","key":"2377_CR12","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.2169\/internalmedicine.55.7367","volume":"55","author":"H Shimohata","year":"2016","unstructured":"Shimohata H, Ogawa Y, Maruyama H, Hirayama K, Kobayashi M. A renal variant of Fabry disease diagnosed by the presence of urinary mulberry cells. Intern Med. 2016;55(23):3475\u20138.","journal-title":"Intern Med"},{"issue":"3","key":"2377_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/0886022X.2011.647300","volume":"34","author":"JS Choi","year":"2012","unstructured":"Choi JS, Kim CS, Park JW, Bae EH, Ma SK, Choi YD, Kim GH, Yoo HW, Kim SW. A novel small insertion mutation, C.1030_1031ins (T) in \u03b1-galactosidase A leads to renal variant fabry disease. Ren Fail. 2012;34(3):390\u20133.","journal-title":"Ren Fail"},{"issue":"5","key":"2377_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ckj\/sfs119","volume":"5","author":"S Al-Salam","year":"2012","unstructured":"Al-Salam S, Chaaban A, Al-Jasmi F, Amann K, Abouchacra S. Renal variant of Fabry disease with sporadic GLA gene mutation: role of early renal biopsy. Clin Kidney J. 2012;5(5):416\u20139.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2377_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1042\/CS20180676","volume":"133","author":"FJ Lin","year":"2019","unstructured":"Lin FJ, Yao L, Hu XQ, Bian F, Ji G, Jiang GR, Gale DP, Ren HQ. First identification of PODXL nonsense mutations in autosomal dominant focal segmental glomerulosclerosis. Clin Sci (Lond). 2019;133(1):9\u201321.","journal-title":"Clin Sci (Lond)"},{"key":"2377_CR16","doi-asserted-by":"crossref","unstructured":"Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. Kidney Int. 2018;94(5):1013\u201322.","DOI":"10.1016\/j.kint.2018.07.024"},{"issue":"3","key":"2377_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.hlc.2007.03.007","volume":"16","author":"N Sadick","year":"2007","unstructured":"Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ. 2007;16(3):200\u20136.","journal-title":"Heart Lung Circ"},{"key":"2377_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","volume":"16","author":"L Zhao","year":"2016","unstructured":"Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:129.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"2377_CR19","doi-asserted-by":"publisher","first-page":"e007168","DOI":"10.1161\/CIRCIMAGING.117.007168","volume":"11","author":"S Nordin","year":"2018","unstructured":"Nordin S, Kozor R, Baig S, Abdel-Gadir A, Medina-Menacho K, Rosmini S, Captur G, Tchan M, Geberhiwot T, Murphy E, et al. Cardiac phenotype of prehypertrophic fabry disease. Circ Cardiovasc Imaging. 2018;11(6):e007168.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"2377_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8\u201316.","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"2377_CR21","doi-asserted-by":"publisher","first-page":"103703","DOI":"10.1016\/j.ejmg.2019.103703","volume":"63","author":"A Smirnova","year":"2020","unstructured":"Smirnova A, Di Toro A, Giuliani L, Tagliani M, Urtis M, Favalli V, Arbustini E. Renal and brain complications in GLA p.Phe113Leu Fabry disease. Eur J Med Genet. 2020;63(2):103703.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"2377_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5455\/annalsmedres.2019.12.875","volume":"27","author":"N Cakar","year":"2020","unstructured":"Cakar N, Barman H. Evaluation of echocardiographic findings of fabry patients: a single center experience. Ann Med Res. 2020;27(2):678\u201381.","journal-title":"Ann Med Res"},{"issue":"12","key":"2377_CR23","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","volume":"19","author":"G Duro","year":"2018","unstructured":"Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri R, Sciarrino S, Francofonte D, et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci. 2018;19(12):3726.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2377_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1086\/376608","volume":"73","author":"M Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Osawa M, Desnick RJ. Fabry disease: novel alpha-galactosidase A 3\u2019-terminal mutations result in multiple transcripts due to aberrant 3\u2019-end formation. Am J Hum Genet. 2003;73(1):162\u201373.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2377_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/339431","volume":"70","author":"S Ishii","year":"2002","unstructured":"Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet. 2002;70(4):994\u20131002.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"2377_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ejhg.2008.109","volume":"16","author":"C Filoni","year":"2008","unstructured":"Filoni C, Caciotti A, Carraresi L, Donati MA, Mignani R, Parini R, Filocamo M, Soliani F, Simi L, Guerrini R, et al. Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients\u2019 fibroblasts results in Fabry disease. Eur J Hum Genet. 2008;16(11):1311\u20137.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2377_CR27","doi-asserted-by":"publisher","first-page":"22372","DOI":"10.1038\/s41598-021-01749-7","volume":"11","author":"A Nowak","year":"2021","unstructured":"Nowak A, Murik O, Mann T, Zeevi DA, Altarescu G. Detection of single nucleotide and copy number variants in the Fabry disease-associated GLA gene using nanopore sequencing. Sci Rep. 2021;11(1):22372.","journal-title":"Sci Rep"},{"key":"2377_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/8904_2015_475","volume":"30","author":"T Higuchi","year":"2016","unstructured":"Higuchi T, Kobayashi M, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, Eto Y, Maeda S, Ohtake A, Ida H, et al. Identification of cryptic novel \u03b1-galactosidase A gene mutations: abnormal mRNA splicing and large deletions. JIMD Rep. 2016;30:63\u201372.","journal-title":"JIMD Rep"},{"issue":"4","key":"2377_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","volume":"31","author":"B Najafian","year":"2020","unstructured":"Najafian B, T\u00f8ndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31(4):865\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2377_CR30","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62(6):1933\u201346.","journal-title":"Kidney Int"},{"issue":"5","key":"2377_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063506","volume":"8","author":"MC Liebau","year":"2013","unstructured":"Liebau MC, Braun F, H\u00f6pker K, Weitbrecht C, Bartels V, M\u00fcller RU, Brodesser S, Saleem MA, Benzing T, Schermer B, et al. Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease. PLoS ONE. 2013;8(5): e63506.","journal-title":"PLoS ONE"},{"issue":"21","key":"2377_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/ijms222111339","volume":"22","author":"U Jehn","year":"2021","unstructured":"Jehn U, Bayraktar S, Pollmann S, Van Marck V, Weide T, Pavenst\u00e4dt H, Brand E, Lenders M. \u03b1-galactosidase a deficiency in Fabry disease leads to extensive dysregulated cellular signaling pathways in human podocytes. Int J Mol Sci. 2021;22(21):256.","journal-title":"Int J Mol Sci"},{"key":"2377_CR33","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2020\/e1811","volume":"75","author":"NB Hasbal","year":"2020","unstructured":"Hasbal NB, Caglayan FB, Sakaci T, Ahbap E, Koc Y, Sevinc M, Ucar ZA, Unsal A, Basturk T. Unexpectedly high prevalence of low alpha-galactosidase A enzyme activity in patients with focal segmental glomerulosclerosis. Clinics (Sao Paulo). 2020;75: e1811.","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"2377_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"J Lukas","year":"2016","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and clinical consequences of novel \u03b1-galactosidase a mutations in Fabry disease. Hum Mutat. 2016;37(1):43\u201351.","journal-title":"Hum Mutat"},{"key":"2377_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1750-1172-9-96","volume":"9","author":"TR Hsu","year":"2014","unstructured":"Hsu TR, Sung SH, Chang FP, Yang CF, Liu HC, Lin HY, Huang CK, Gao HJ, Huang YH, Liao HC, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis. 2014;9:96.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2377_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ymgme.2016.08.007","volume":"119","author":"B Palhais","year":"2016","unstructured":"Palhais B, Dembic M, Sabaratnam R, Nielsen KS, Doktor TK, Bruun GH, Andresen BS. The prevalent deep intronic c.639+919 G>A GLA mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2\/B1 to a splicing silencer. Mol Genet Metab. 2016;119(3):258\u201369.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2377_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10545-010-9166-7","volume":"33","author":"HY Lin","year":"2010","unstructured":"Lin HY, Huang CH, Yu HC, Chong KW, Hsu JH, Lee PC, Cheng KH, Chiang CC, Ho HJ, Lin SP, et al. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4+919G\u2192A). J Inherit Metab Dis. 2010;33(5):619\u201324.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02377-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:14:43Z","timestamp":1655723683000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02377-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2377"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02377-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the involved subjects and all procedures were performed in accordance with the Declaration of Helsinki. The study was performed under the approval of the Ethics Committee from Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine (approval no. XHEC-D-2020-002). All participants gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the submission of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}